Selective regulation of IL-10 signaling and function by zymosan

Journal of Immunology

Volumn 176, Issue 8, 2006, Pages 4785-4792

  Du, Zhimei ^a   Kelly, Erin ^a   Mecklenbräuker, Ingrid ^b   Agle, Lucila ^c   Herrero, Carmen ^c   Paik, Paul ^c   Ivashkiv, Lionel B ^a,c  

^a Weill Cornell Graduate School of Biomedical Sciences   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; PROTEIN KINASE C BETA; ZYMOSAN;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; AUTOIMMUNITY; CELL INTERACTION; CELL PROTECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; INFLAMMATION; INTERNALIZATION; MACROPHAGE ACTIVATION; MICROENVIRONMENT; PARACRINE SIGNALING; PHAGOCYTOSIS; PRIORITY JOURNAL; REGULATORY MECHANISM; TISSUE INJURY;

EID: 33645761634     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.8.4785     Document Type: Article

References (45)

1. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19: 683-765.
2. Dower, S. K. 2000. Cytokines, virokines and the evolution of immunity. Nat. Immunol. 1: 367-368.
3. Liese, A. M., M. Q. Siddiqi, J. H. Siegel, T. Denny, and Z. Spolarics. 2001. Augmented TNF-α and IL-10 production by primed human monocytes following interaction with oxidatively modified autologous erythrocytes. J. Leukocyte Biol. 70: 289-296.
4. Platzer, C., C. Meisel, K. Vogt, M. Platzer, and H. D. Volk. 1995. Up-regulation of monocytic IL-10 by tumor necrosis factor-α and cAMP elevating drugs. Int. Immunol. 7: 517-523.
5. 2. J. Exp. Med. 180: 2365-2370.
6. Marchant, A., J. Deviere, B. Byl, D. De Groote, J. L. Vincent, and M. Goldman. 1994. Interleukin-10 production during septicaemia. Lancet 343: 707-708.
7. van der Poll, T., and S. J. van Deventer. 1999. Cytokines and anticytokines in the pathogenesis of sepsis. Infect. Dis. Clin. North Am. 13: 413-426.
8. Oberholzer, A., C. Oberholzer, and L. L. Moldawer. 2002. Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an antiinflammatory drug. Crit. Care Med. 30: S58-S63.
9. Tilg, H., C. van Montfrans, A. van den Ende, A. Kaser, S. J. van Deventer, S. Schreiber, M. Gregor, O. Ludwiczek, P. Rutgeerts, C. Gasche, et al. 2002. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon γ. Gut 50: 191-195.
10. Fedorak, R. N., A. Gangl, C. O. Elson, P. Rutgeerts, S. Schreiber, G. Wild, S. B. Hanauer, A. Kilian, M. Cohard, A. LeBeaut, and B. Feagan. 2000. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease: the Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119: 1473-1482.
11. Gantner, B. N., R. M. Simmons, S. J. Canavera, S. Akira, and D. M. Underhill. 2003. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J. Exp. Med. 197: 1107-1117.
12. Di Carlo, F. J., and J. V. Fiore. 1958. On the composition of zymosan. Science 127: 756-757.
13. Pillemer, L., and E. E. Ecker. 1941. Anticomplementary factor in fresh yeast. J. Biol. Chem. 137: 139-142.
14. Brown, G. D., J. Herre, D. L. Williams, J. A. Willmem, A. S. Marshall, and S. Gordon. 2003. Dectin-1 mediates the biological effects of β-glucans. J. Exp. Med. 197: 1119-1124.
15. Rogers, N. C., E. C. Slack, A. D. Edwards, M. A. Nolte, O. Schulz, E. Schweighoffer, D. L. Williams, S. Gordon, V. L. Tybulewicz, G. D. Brown, and C. Reis e Sousa. 2005. Syk-dependent cytokine induction by dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity 22: 507-517.
16. Yoshitomi, H., N. Sakaguchi, K. Kobayashi, G. D. Brown, T. Tagami, T. Sakihama, K. Hirota, S. Tanaka, T. Nomura, I. Miki, et al. 2005. A role for fungal β-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. J. Exp. Med. 201: 949-960.
17. Ahmed, S. T., and L. B. Ivashkiv. 2000. Inhibition of IL-6 and IL-10 signaling and Stat activation by inflammatory and stress pathways. J. Immunol. 165: 5227-5237.
18. Ji, J.-D., I. Tassiulas, K.-H. Park-Min, A. Aydin, I. Mecklenbräuker, A. Tarakhovsky, L. Pricop, J. E. Salmon, and L. B. Ivashkiv. 2003. Inhibition of interleukin 10 signaling after Fc receptor ligation and during rheumatoid arthritis. J. Exp. Med. 197: 1573-1583.
19. Rajagopal, R., Z. Y. Chen, F. S. Lee, and M. V. Chao. 2004. Transactivation of Trk neurotrophin receptors by G-protein-coupled receptor ligands occurs on intracellular membranes. J. Neurosci. 24: 6650-6658.
20. Riley, J. K., K. Takeda, S. Akira, and R. D. Schreiber. 1999. Interleukin-10 receptor signaling through the JAK-STAT pathway: requirement for two distinct receptor-derived signals for anti-inflammatory action. J. Biol. Chem. 274: 16513-16521.
21. Takeda, K., B. E. Clausen, T. Kaisho, T. Tsujimura, N. Terada, I. Forster, and S. Akira. 1999. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of StatS in macrophages and neutrophils. Immunity 10: 39-49.
22. Réglier-Poupet, H., J. Hakim, M. A. Gougerot-Pocidalo, and C. Elbim. 1998. Absence of regulation of human polymorphonuclear oxidative burst by interleukin-10, interleukin-4, interleukin-13 and transforming growth factor-β in whole blood. Eur. Cytokine Netw. 9: 633-638.
23. Ahmed, S. T., A. Mayer, J.-D. Ji, and L. B. Ivashkiv. 2002. Inhibition of IL-6 signaling by a p38-dependent pathway occurs in the absence of new protein synthesis. J. Leukocyte Biol. 72: 154-162.
24. Deon, D., S. Ahmed, K. Tai, N. Scaletta, C. Herrero, I. H. Lee, A. Krause, and L. B. Ivashkiv. 2001. Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts. J. Immunol. 167: 5395-5403.
25. Sengupta, T. K., E. M. Schmitt, and L. B. Ivashkiv. 1996. Inhibition of cytokines and JAK-STAT activation by distinct signaling pathways. Proc. Natl. Acad. Sci. USA 93: 9499-9504.
26. Sengupta, T. K., E. S. Talbot, P. A. Scherle, and L. B. Ivashkiv. 1998. Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases. Proc. Natl. Acad. Sci. USA 95: 11107-11112.
27. Petricoin, E., III, M. David, K. Igarashi, C. Benjamin, L. Ling, S. Goelz, D. S. Finbloom, and A. C. Larner. 1996. Inhibition of α interferon but not γ interferon signal transduction by phorbol esters is mediated by a tyrosine phosphatase. Mol. Cell. Biol. 16: 1419-1424.
28. Nguyen, V. A., J. Chen, F. Hong, E. J. Ishac, and B. Gao. 2000. Interferons activate the p42/44 mitogen-activated protein kinase and JAK-STAT (Janus kinase-signal transducer and activator transcription factor) signalling pathways in hepatocytes: differential regulation by acute ethanol via a protein kinase C-dependent mechanism. Biochem. J. 349: 427-434.
29. Zhu, J., H. Huang, L. Guo, T. Stonehouse, C. J. Watson, J. Hu-Li, and W. E. Paul. 2000. Transient inhibition of interleukin 4 signaling by T cell receptor ligation. J. Exp. Med. 192: 1125-1134.
30. Lee, I. H., W. P. Li, K. B. Hisert, and L. B. Ivashkiv. 1999. Inhibition of interleukin 2 signaling and signal transducer and activator of transcription (STAT)5 activation during T cell receptor-mediated feedback inhibition of T cell expansion. J. Exp. Med. 190: 1263-1274.
31. Tian, Z.-J., W. Cui, Y.-J. Li, Y.-M. Hao, J. Du, F. Liu, H. Zhang, X.-G. Zu, S.-Y. Liu, L. Chen, and W. An. 2004. Different contributions of STAT3, ERK1/2, and PI3-K signaling to cardiomyocyte hypertrophy by cardiotrophin-1. Acta Pharmacol. Sin. 25: 1157-1164.
32. Mecklenbräuker, I., K. Saijo, N.-Y. Zheng, M. Leitges, and A. Tarakhovsky. 2002. Protein kinase Cδ controls self-antigen-induced B-cell tolerance. Nature 416: 860-865.
33. Leitges, M., C. Schmedt, R. Guinamard, J. Davoust, S. Schaal, S. Stabel, and A. Tarakhovsky. 1996. Immunodeficiency in protein kinase cβ-deficient mice. Science 273: 788-791.
34. Qureshi, S. T., and R. Medzhitov. 2003. Toll-like receptors and their role in experimental models of microbial infection. Genes Immun. 4: 87-94.
35. Sabroe, I., L. R. Prince, E. C. Jones, M. J. Horsburgh, S. J. Foster, S. N. Vogel, S. K. Dower, and M. K. Whyte. 2003. Selective roles for Toll-like receptor (TLR)2 and TLR4 in the regulation of neutrophil activation and life span. J. Immunol. 170: 5268-5275.
36. Takeda, K., and S. Akira. 2005. Toll-like receptors in innate immunity. Int. Immunol. 17: 1-14.
37. Guinamard, R., N. Signoret, M. Ishiai, M. Marsh, T. Kurosaki, and J. V. Ravetch. 1999. B cell antigen receptor engagement inhibits stromal cell-derived factor (SDF)-1α chemotaxis and promotes protein kinase C (PKC)-induced internalization of CXCR4. J. Exp. Med. 189: 1461-1466.
38. Sharif, M. N., I. Tassiulas, Y. Hu, I. Mecklenbräuker, A. Tarakhovsky, and L. B. Ivashkiv. 2004. IFN-α priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J. Immunol. 172: 6476-6481.
39. Hu, X., W. P. Li, C. Meng, and L. B. Ivashkiv. 2003. Inhibition of IFN-γ signaling by glucocorticoids. J. Immunol. 170: 4833-4839.
40. Tassiulas, I., X. Hu, H. Ho, Y. Kashyap, P. Paik, Y. Hu, C. A. Lowell, and L. B. Ivashkiv. 2004. Amplification of IFN-α-induced STAT1 activation and inflammatory function by Syk and ITAM-containing adaptors. Nat. Immunol. 5: 1181-1189.
41. Herrero, C., X. Hu, W. P. Li, S. Samuels, M. N. Sharif, S. Kotenko, and L. B. Ivashkiv. 2003. Reprogramming of IL-10 activity and signaling by IFN-γ. J. Immunol. 171: 5034-5041.
42. Ron, D., J. Luo, and D. Mochly-Rosen. 1995. C2 region-derived peptides inhibit translocation and function of β protein kinase C in vivo. J. Biol. Chem. 270: 24180-24187.
43. Souroujon, M. C., and D. Mochly-Rosen. 1998. Peptide modulators of protein-protein interactions in intracellular signaling. Nat. Biotechnol. 16: 919-924.
44. Yedovitzky, M., D. Mochly-Rosen, J. A. Johnson, M. O. Gray, D. Ron, E. Abramovitch, E. Cerasi, and R. Nesher. 1997. Translocation inhibitors define specificity of protein kinase C isoenzymes in pancreatic β cells. J. Biol. Chem. 272: 1417-1420.
45. Johnson, J. A., M. O. Gray, C. H. Chen, and D. Mochly-Rosen. 1996. A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function. J. Biol. Chem. 271: 24962-24966.